SCHEMBL4922362

SCHEMBL4922362

COC(=O)OCCCCC(C)C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.40
ZDHHC7 Q9NXF8 1/20 0.37
LMNA P02545 1/20 0.37
KDM4C Q9H3R0 2/20 0.37
KDM4A O75164 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BLM P54132 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
EPHX1 P07099 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
ACHE P22303 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339147 0.98 ZDHHC7 (0.40) RARBZDHHC7LMNAKDM4CKDM4A
SCHEMBL28272922 0.98 ZDHHC7 (0.40) RARBZDHHC7LMNAKDM4CKDM4A
SCHEMBL38664127 0.98 ZDHHC7 (0.40) RARBZDHHC7LMNAKDM4CKDM4A
SCHEMBL38662162 0.98 ZDHHC7 (0.40) RARBZDHHC7LMNAKDM4CKDM4A
SCHEMBL5511600 0.93 PKM (0.38) RARBZDHHC7KDM4CKDM4APHF8
SCHEMBL2347061 0.91 RARB (0.42) RARBLMNAKDM4CKDM4APHF8
SCHEMBL345909 0.89 RARB (0.41) RARBLMNAKDM4CKDM4APHF8
SCHEMBL1940168 0.89 RARB (0.41) RARBLMNAKDM4CKDM4APHF8
SCHEMBL3151344 0.89 RARB (0.41) RARBLMNAKDM4CKDM4APHF8
SCHEMBL2338283 0.89 RARB (0.41) RARBLMNAKDM4CKDM4APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
US-9616099-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2017-04-11 US disclosed
US-9616099-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2017-04-11 US disclosed
US-20160136233-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION ENANTA PHARM INC (US) 2016-05-19 US disclosed
US-9221878-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2015-12-29 US disclosed
US-20150056165-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION ENANTA PHARMACEUTICALS, INC. 2015-02-26 US disclosed
US-20080161394-A1 Cosmetic composition comprising at least one volatile carbonic acid ester L'OREAL S.A. (FR) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160136233-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION HAVCR2, CHP1, MAVS RARB 3875/4885ZDHHC7 468/4885LMNA 4263/4885
US-20150056165-A1 NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION HAVCR2, CHP1, MAVS RARB 3875/4885ZDHHC7 468/4885LMNA 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.